201 related articles for article (PubMed ID: 26255027)
21. Role of bone marrow adipocytes in leukemia and chemotherapy challenges.
Samimi A; Ghanavat M; Shahrabi S; Azizidoost S; Saki N
Cell Mol Life Sci; 2019 Jul; 76(13):2489-2497. PubMed ID: 30715556
[TBL] [Abstract][Full Text] [Related]
22. The hypoxic tumor microenvironment: A driving force for breast cancer progression.
Semenza GL
Biochim Biophys Acta; 2016 Mar; 1863(3):382-391. PubMed ID: 26079100
[TBL] [Abstract][Full Text] [Related]
23. Tumour microenvironment and metabolic plasticity in cancer and cancer stem cells: Perspectives on metabolic and immune regulatory signatures in chemoresistant ovarian cancer stem cells.
Ahmed N; Escalona R; Leung D; Chan E; Kannourakis G
Semin Cancer Biol; 2018 Dec; 53():265-281. PubMed ID: 30317036
[TBL] [Abstract][Full Text] [Related]
24. Exosome-mediated microenvironment dysregulation in leukemia.
Kumar B; Garcia M; Murakami JL; Chen CC
Biochim Biophys Acta; 2016 Mar; 1863(3):464-470. PubMed ID: 26384870
[TBL] [Abstract][Full Text] [Related]
25. The Bone Marrow Niche - The Tumor Microenvironment That Ensures Leukemia Progression.
Cardoso BA
Adv Exp Med Biol; 2020; 1219():259-293. PubMed ID: 32130704
[TBL] [Abstract][Full Text] [Related]
26. Human bone marrow niche chemoprotection mediated by cytochrome P450 enzymes.
Alonso S; Su M; Jones JW; Ganguly S; Kane MA; Jones RJ; Ghiaur G
Oncotarget; 2015 Jun; 6(17):14905-12. PubMed ID: 25915157
[TBL] [Abstract][Full Text] [Related]
27. The Microenvironment of Lung Cancer and Therapeutic Implications.
Mittal V; El Rayes T; Narula N; McGraw TE; Altorki NK; Barcellos-Hoff MH
Adv Exp Med Biol; 2016; 890():75-110. PubMed ID: 26703800
[TBL] [Abstract][Full Text] [Related]
28. Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104.
Benito J; Shi Y; Szymanska B; Carol H; Boehm I; Lu H; Konoplev S; Fang W; Zweidler-McKay PA; Campana D; Borthakur G; Bueso-Ramos C; Shpall E; Thomas DA; Jordan CT; Kantarjian H; Wilson WR; Lock R; Andreeff M; Konopleva M
PLoS One; 2011; 6(8):e23108. PubMed ID: 21853076
[TBL] [Abstract][Full Text] [Related]
29. The Role of the Microenvironment and Immune System in Regulating Stem Cell Fate in Cancer.
Ferguson LP; Diaz E; Reya T
Trends Cancer; 2021 Jul; 7(7):624-634. PubMed ID: 33509688
[TBL] [Abstract][Full Text] [Related]
30. Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models.
Benito J; Ramirez MS; Millward NZ; Velez J; Harutyunyan KG; Lu H; Shi YX; Matre P; Jacamo R; Ma H; Konoplev S; McQueen T; Volgin A; Protopopova M; Mu H; Lee J; Bhattacharya PK; Marszalek JR; Davis RE; Bankson JA; Cortes JE; Hart CP; Andreeff M; Konopleva M
Clin Cancer Res; 2016 Apr; 22(7):1687-98. PubMed ID: 26603259
[TBL] [Abstract][Full Text] [Related]
31. Role of Microenvironment in Non-Hodgkin Lymphoma: Understanding the Composition and Biology.
Khurana A; Ansell SM
Cancer J; 2020; 26(3):206-216. PubMed ID: 32496454
[TBL] [Abstract][Full Text] [Related]
32. Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach.
Taylor S; Spugnini EP; Assaraf YG; Azzarito T; Rauch C; Fais S
Drug Resist Updat; 2015 Nov; 23():69-78. PubMed ID: 26341193
[TBL] [Abstract][Full Text] [Related]
33. Metabolic regulation of the bone marrow microenvironment in leukemia.
Xu B; Hu R; Liang Z; Chen T; Chen J; Hu Y; Jiang Y; Li Y
Blood Rev; 2021 Jul; 48():100786. PubMed ID: 33353770
[TBL] [Abstract][Full Text] [Related]
34. Bone marrow microenvironment confers imatinib resistance to chronic myelogenous leukemia and oroxylin A reverses the resistance by suppressing Stat3 pathway.
Li X; Miao H; Zhang Y; Li W; Li Z; Zhou Y; Zhao L; Guo Q
Arch Toxicol; 2015 Jan; 89(1):121-36. PubMed ID: 24671465
[TBL] [Abstract][Full Text] [Related]
35. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
Shapira A; Livney YD; Broxterman HJ; Assaraf YG
Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
[TBL] [Abstract][Full Text] [Related]
36. Targeting the leukemia microenvironment.
Konopleva M; Andreeff M
Curr Drug Targets; 2007 Jun; 8(6):685-701. PubMed ID: 17584025
[TBL] [Abstract][Full Text] [Related]
37. Targeting the microenvironment in acute myeloid leukemia.
Rashidi A; Uy GL
Curr Hematol Malig Rep; 2015 Jun; 10(2):126-31. PubMed ID: 25921388
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic Targeting of the Leukaemia Microenvironment.
Kuek V; Hughes AM; Kotecha RS; Cheung LC
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206957
[TBL] [Abstract][Full Text] [Related]
39. Immune ligands for cytotoxic T Lymphocytes (CTLS) in cancer stem cells (CSCS).
Voutsadakis IA
Front Biosci (Landmark Ed); 2018 Jan; 23(3):563-583. PubMed ID: 28930561
[TBL] [Abstract][Full Text] [Related]
40. Multistep targeted nano drug delivery system aiming at leukemic stem cells and minimal residual disease.
Shi Y; Su Z; Li S; Chen Y; Chen X; Xiao Y; Sun M; Ping Q; Zong L
Mol Pharm; 2013 Jun; 10(6):2479-89. PubMed ID: 23646913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
